Characteristics of eligible trials.

<p>CT, computed tomography; comp, comparative; d, day; diam, diameter; max, maximum; mm, millimeter; mo, month; multi, multicenter; MRI, magnetic resonance imaging; non–comp, non-comparative; non–rand, non-randomized; obs, observational; OCT LAR, intramuscular octreotide long-acting repeatable; OCT sc, octreotide subcutaneous; open, open-label; pts: patients; prosp, prospective; rand, randomized; retro, retrospective; RTX, radiotherapy; SSA, somatostatin analogs; single, single-center; SUR, surgery; TS, tumor shrinkage; unk, unknown; wk week.</p

Search strategy and results.

<p>Search strategy and results.</p

Univariate analysis of factors associated with tumor response.

<p>CI, confidence interval; OCT, octreotide; OCT-LAR, octreotide long-acting repeatable; MICRO, microadenoma; MACRO, macroadenoma; GH, growth hormone; IGF-I, insulin-like growth factor-I.</p

Search strategy used to identify eligible published clinical trials.

<p>Search strategy used to identify eligible published clinical trials.</p

Forest plot depicting the proportion of patients with and without a reduction in tumor size CI, confidence interval.

<p>Forest plot depicting the proportion of patients with and without a reduction in tumor size CI, confidence interval.</p

Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s12325-016-0358-x">https://link.springer.com/article/10.1007/s12325-016-0358-x</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

Association with OS (Cox proportional hazard model).

<p>Association with OS (Cox proportional hazard model).</p

Distribution according to tumor size in Luminal A and Luminal B tumors.

<p>Distribution according to tumor size in Luminal A and Luminal B tumors.</p

OS for different molecular subtype.

<p>OS for different molecular subtype.</p

Association with DFS in the Luminal A patients (Cox proportional hazard model).

<p>Association with DFS in the Luminal A patients (Cox proportional hazard model).</p